Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Bio

The Future of Cancer Treatment Is Here — And It Starts with the Right Clinical Trial

Cancer research no longer moves slowly; it advances rapidly. Revolutionary discoveries in precision medicine, immunotherapy, and gene editing emerge almost weekly, yet many patients still confront enormous hurdles when they look for cutting‑edge options.

International Business Times

Do Wall Street Analysts Like Bio-Techne Stock?

Bio-Techne has notably underperformed the broader market over the past year, and analysts remain cautiously optimistic about the stock’s prospects.

Barchart

Is Bio-Techne Corporation Stock Underperforming the S&P 500?

Despite Bio-Techne Corporation’s underperformance relative to the S&P 500 over the past year, analysts maintain a bullish outlook on the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Biotech group warns exit of top FDA vaccine official will ‘erode scientific standards’

Rare admonition from a sector that has largely been silent in the face of the second Trump administration

The Guardian - US

Bio-Techne Stock Outlook: Is Wall Street Bullish or Bearish?

Despite Bio-Techne's underperformance relative to the broader market over the past year, Wall Street analysts remain bullish on the stock's prospects.

Barchart

Cryonics Start-Up Extending Life For $200,000 Sparks Hilarious Reactions

"I swear I've seen this movie." The post Cryonics Start-Up Extending Life For $200,000 Sparks Hilarious Reactions first appeared on Bored Panda.

Bored Panda

Bio-Techne Shows Improved Relative Strength; Still Shy Of Benchmark

A Relative Strength Rating upgrade for Bio-Techne shows improving technical performance. Will it continue?

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Is This Penny Stock a Buy After a 180% Rally?

Bio-Path Holdings surged 180% on promising obesity drug results. Discover why this penny stock's pivot from cancer treatments and Nasdaq delisting challenges could matter for investors.

Barchart

Are Wall Street Analysts Predicting Bio-Techne Stock Will Climb or Sink?

Bio-Techne has underperformed the broader market over the past year, yet analysts remain bullish on the stock’s prospects.

Barchart

16 best probiotics to help improve gut health

Support your gut health, boost your immune system and reduce bloating with these probiotic supplements

The Independent UK

Bio-Rad Laboratories Stock: Is BIO Underperforming the Healthcare Sector?

Despite Bio-Rad Laboratories’ underperformance relative to the healthcare sector over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?

Bio-Techne has underperformed the healthcare sector over the past year, yet analysts remain strongly bullish about the stock’s prospects.

Barchart

Congress targets Chinese influence in health tech. It could come with tradeoffs

A San Jose-based biotechnology company that helps doctors detect genetic causes for cancer is among those that could be cut out of the U.S. market over ties to China

The Independent UK

Is Wall Street Bullish or Bearish on Bio-Techne Stock?

Bio-Techne has underperformed the broader market this year, but Wall Street analysts are optimistic about the stock’s prospects.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

International Business Times

How Bio-Safe By BioSecurity Technology Is Setting The New Standard Of Clean

Central to Bio-Safe's strategy is rigorous biofilm control and removal, annihilating the chances of viruses inhabiting it by destroying the protein bonds that protect residing microorganisms.

Barchart

What to Expect From Bio-Techne’s Next Quarterly Earnings Report

With Bio-Techne gearing up to release its fourth-quarter earnings next month, analysts project a double-digit earnings decline.

Barchart

What You Need to Know Ahead of Bio-Rad Laboratories' Earnings Release

Bio-Rad Laboratories is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit dip.

Investors Business Daily

Bio Stock Procept BioRobotics Eyes Rare Buy Trigger After Earnings

Bio stock leader Procept BioRobotics is within striking distance of a new buy trigger after reporting earnings late Tuesday.

Get all your
news in one place.

100’s of premium titles.
One news app.

Evening Standard

Butyrate: forget probiotics, this is why you need a postbiotic

Is this postbiotic the missing link for improved gut health? Nutritionist Louise Pyne investigates

Chicago Sun-Times

Weed dispensary plan at old Rainforest Cafe in River North goes up in smoke

Two lawsuits sought to block the joint venture between Progressive Treatment Solutions LLC and Bio-Pharm for an outlet at 605 N. Clark St.

StockNews.com

Are These 3 Medical Stocks Worth Buying?

The increased demand for healthcare services and technological advancements are poised to keep the healthcare industry buoyed in the foreseeable future. Given this backdrop, are medical stocks Danaher Corporation (DHR), IQVIA Holdings (IQV), and Bio-Rad Laboratories (BIO) worth buying now? Read on to find more….

Daily Mirror

Nine 'healthy' habits that aren't as good as you think - from chewing gum to exercise

People may be surprised to hear some of the everyday healthy habits which may not be as good for you as previously believed, such as skipping all fatty foods

Daily Record

Nine 'healthy' habits that may be causing damage if overdone

Some things that are often seen as good for your health could be causing more harm than good.

Daily Mirror

Nine 'healthy habits' that could do more harm than good - including eating too much veg

Other common habits that can actually be detrimental to your health include taking too many supplements, brushing your teeth too much and chewing gum

Investors Business Daily

Why Bio-Rad Laboratories' Rumored $10 Billion Qiagen Buyout Looks Unlikely

A rumored matchup between Bio-Rad Laboratories and Qiagen is unlikely, an analyst said Tuesday as BIO stock fell for a second straight day.

1 2

People

Sristi Suman JayaswalThe

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.